Coronavirus pharma news roundup – 19/06/20
Boston partnership leverages local manufacturing to quickly produce reusable face shields
Needham: 3 Conviction Buy Stocks to Snap up Now
2 “Strong Buy” Small-Cap Stocks That Could See Outsized Gains
US left with huge hydroxychloroquine stockpile after COVID-19 trial failures
MRNA Stock Price Jumps On Finalizing FDA Phase 3 Study for Coronavirus Vaccine
3 Pharmaceutical Stocks With Major Catalysts Approaching
3 “Strong Buy” Healthcare Stocks That Should Remain Healthy
3 "Strong Buy" Pharmaceutical Stocks With Major Catalysts Approaching
Chembio Sinks 59% In Pre-Market As FDA Revokes Its Covid-19 Test; Top Analyst Cuts Rating
Kamada’s Covid-19 Therapy Approved For Compassionate Use In Israel
Fulgent Pops 18% In After-Market On FDA Nod For Covid-19 Home Test
UK stops recruitment to hydroxychloroquine COVID-19 trials
FDA warns against combination of malaria drug and Gilead’s remdesivir
Beijing Bars 'High Risk' Residents From Leaving, Closes 7 Compounds As Lockdowns Return
The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug
’Omics in Translation
U.S. FDA revokes emergency use status of drug touted by Trump for COVID-19
FDA Withdraws Emergency Authorization For Hydroxychloroquine After HHS Official Makes Request
Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir
The unprecedented challenge of pricing a coronavirus vaccine
Houston "On The Precipice Of Disaster" As Officials Weigh Reimposing Stay At Home Order Amid Spike In Cases: Live Updates
Finding health care companies we believe can thrive in a post-COVID-19 environment
Nation must prepare for COVID-19 related drug shortages
Celltrion trials infliximab biosimilar in recovering COVID-19 patients
Sorrento Soars 17% In Pre-Market On Covid-19 Test Application
Digital health predicted as the new normal in COVID aftermath
Scientists use machine learning to predict major clinical forms of drug cardiotoxicity
Regeneron joins $100M round for DNAnexus and its cloud-computing DNA software
Sorrento’s COVID-19 Cocktail Could Drive Major Upside, Says Analyst